Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adverum Biotechnologies, Inc.ADVM · Entity 71889 | Director | May 12, 2021 | May 14, 2021 |
| Aligos Therapeutics, Inc.ALGS · Entity 7352 | Director | June 23, 2022 | June 27, 2022 |
| CRISPR Therapeutics AGCRSP · Entity 3852 | Director | June 15, 2018 | June 16, 2018 |
| Gritstone bio, Inc.GRTS · Entity 80946 | Director | August 25, 2021 | August 27, 2021 |
| Passage BIO, Inc.PASG · Entity 7829 | Director · 10% owner | May 25, 2023 | May 26, 2023 |
| Tempest Therapeutics, Inc.TPST · Entity 7734 | Director | June 17, 2022 | June 22, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adverum Biotechnologies, Inc.
Report date May 12, 2021 · Filed May 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.70 · Expires 2031-05-11 | Direct | 40,000 |
Reported balance
After 2021-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-12 · Grant · Acquired 40,000 · Balance 40,000 F1: The shares subject to the option will vest on the earlier of May 12, 2022 or the 2022 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of May 12, 2022 or the 2022 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date.
Aligos Therapeutics, Inc.
Report date June 23, 2022 · Filed June 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.34 · Expires 2032-06-23 | Direct | 15,000 |
Reported balance
After 2022-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-23 · Grant · Acquired 15,000 · Balance 15,000 F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2023 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2023 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date.
CRISPR Therapeutics AG
Report date June 15, 2018 · Filed June 16, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.31 · Expires 2028-06-15 | IndirectSee Footnotes | 30,000 |
Reported balance
After 2018-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-15 · Grant · Acquired 30,000 · Balance 30,000 F2: One-half of the securities acquired as reported in column 5 were granted to the Reporting Person and one-half were granted to Bradley Bolzon, each grant as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person and one-half of the reported securities are held by Mr. Bolzon. Each of the Reporting Person and Mr. Bolzon are managing members of Versant Venture Management, LLC and pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Bolzon are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC. F3: (Continued from Footnote 2) The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F1: This option was granted on June 15, 2018 100% of the shares vesting in 12 equal monthly installments beginning on May 30, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 15, 2018 100% of the shares vesting in 12 equal monthly installments beginning on May 30, 2018.
F2: One-half of the securities acquired as reported in column 5 were granted to the Reporting Person and one-half were granted to Bradley Bolzon, each grant as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person and one-half of the reported securities are held by Mr. Bolzon. Each of the Reporting Person and Mr. Bolzon are managing members of Versant Venture Management, LLC and pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Bolzon are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC.
F3: (Continued from Footnote 2) The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
Gritstone bio, Inc.
Report date August 25, 2021 · Filed August 27, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 902,965 |
Reported balance
After 2021-08-25 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2021-08-25 · Other · Disposed 444,744 · Balance 902,965 F1: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I, L.P. ("VV I") to its partners pursuant to a Rule 10b5-1 trading plan. F2: Shares held by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("VV I GP") and VV I GP is the sole general partner of VV I. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I. Each of VV I GP-GP, VV I GP, and the Reporting Person disclaims beneficial ownership of the shares held by VVI, except to the extent of their respective pecuniary interests therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 6,668 |
Reported balance
After 2021-08-25 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2021-08-25 · Other · Acquired 6,668 · Balance 6,668 F3: Represents a change in the form of ownership of VV I GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VV I. F4: Shares held by VV I GP. VV I GP-GP is the sole general partner of VV I GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP. Each of VV I GP-GP and the Reporting Person disclaims beneficial ownership of the shares held by VV I GP, except to the extent of their respective pecuniary interests therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2021-08-25 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2021-08-25 · Other · Disposed 6,668 · Balance 0 F5: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV I GP, to its partners. F4: Shares held by VV I GP. VV I GP-GP is the sole general partner of VV I GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP. Each of VV I GP-GP and the Reporting Person disclaims beneficial ownership of the shares held by VV I GP, except to the extent of their respective pecuniary interests therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 6,612 |
Reported balance
After 2021-08-25 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2021-08-25 · Other · Acquired 6,612 · Balance 6,612 F6: Represents a change in the form of ownership of VV I GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VV I GP. F7: Shares held by VV I GP-GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2021-08-25 transaction · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · 2021-08-25 · Other · Disposed 6,612 · Balance 0 F8: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV I GP-GP, to its members. F7: Shares held by VV I GP-GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,723,031 |
Reported balance
Holding disclosure · report date 2021-08-25 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 2,723,031 F10: Shares held by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VVC V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VVC V, except to the extent of their respective pecuniary interests therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 81,908 |
Reported balance
Holding disclosure · report date 2021-08-25 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 81,908 F11: Shares held by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VAF V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VAF V, except to the extent of their respective pecuniary interests therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 90,756 |
Reported balance
Holding disclosure · report date 2021-08-25 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 90,756 F12: Shares held by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I"). VV V is the sole general partner of VOAF I. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VOAF I. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VOAF I, except to the extent of their respective pecuniary interests therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 207,234 |
Reported balance
Holding disclosure · report date 2021-08-25 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 207,234 F13: Shares held by Versant Venture Capital V (Canada) LP ("VVC V (Canada)"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V (Canada) GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V (Canada)") and VV V (Canada) is the sole general partner of VVC V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VVC V (Canada). Each of VV V (Canada), VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of their respective pecuniary interests therein, if any. |
| Common StockSEC Table I · non-derivative | Direct | 128 |
Reported balance
After 2021-08-25 transaction · row 6
1 source rowRow 6 · 2021-08-25 · Other · Acquired 128 · Balance 128 F9: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VV I GP-GP. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I, L.P. ("VV I") to its partners pursuant to a Rule 10b5-1 trading plan.
F2: Shares held by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("VV I GP") and VV I GP is the sole general partner of VV I. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I. Each of VV I GP-GP, VV I GP, and the Reporting Person disclaims beneficial ownership of the shares held by VVI, except to the extent of their respective pecuniary interests therein, if any.
F3: Represents a change in the form of ownership of VV I GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VV I.
F4: Shares held by VV I GP. VV I GP-GP is the sole general partner of VV I GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP. Each of VV I GP-GP and the Reporting Person disclaims beneficial ownership of the shares held by VV I GP, except to the extent of their respective pecuniary interests therein, if any.
F5: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV I GP, to its partners.
F6: Represents a change in the form of ownership of VV I GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VV I GP.
F7: Shares held by VV I GP-GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.
F8: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV I GP-GP, to its members.
F9: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VV I GP-GP.
F10: Shares held by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VVC V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VVC V, except to the extent of their respective pecuniary interests therein, if any.
F11: Shares held by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VAF V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VAF V, except to the extent of their respective pecuniary interests therein, if any.
F12: Shares held by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I"). VV V is the sole general partner of VOAF I. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VOAF I. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VOAF I, except to the extent of their respective pecuniary interests therein, if any.
F13: Shares held by Versant Venture Capital V (Canada) LP ("VVC V (Canada)"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V (Canada) GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V (Canada)") and VV V (Canada) is the sole general partner of VVC V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VVC V (Canada). Each of VV V (Canada), VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of their respective pecuniary interests therein, if any.
Passage BIO, Inc.
Report date May 25, 2023 · Filed May 26, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2033-05-24 | Direct | 24,000 |
Reported balance
After 2023-05-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-25 · Grant · Acquired 24,000 · Balance 24,000 F1: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2024 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2024 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date.
Tempest Therapeutics, Inc.
Report date June 17, 2022 · Filed June 22, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.08 · Expires 2032-06-16 | Direct | 3,500 |
Reported balance
After 2022-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-17 · Grant · Acquired 3,500 · Balance 3,500 F1: Vests over one (1) year, with one hundred per cent (100%) of the award vesting on the first anniversary of the date of grant subject to the reporting person's continuous service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Vests over one (1) year, with one hundred per cent (100%) of the award vesting on the first anniversary of the date of grant subject to the reporting person's continuous service through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 20, 2018 Filed Apr 24, 2018 23:42 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 92,918 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-010683 · doc4.xml · nonDerivative · entry 4 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F7 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV IV without consideration to its members. F6 · ownership.nature: The shares are held by VV IV. Read SEC document |
| April 20, 2018 Filed Apr 24, 2018 23:42 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 92,918 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-010683 · doc4.xml · nonDerivative · entry 3 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 92,918 F5 · kind: Represents a change in the form of ownership of VV IV by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC IV and VSF IV. F6 · ownership.nature: The shares are held by VV IV. Read SEC document |
| April 20, 2018 Filed Apr 24, 2018 23:42 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 2,947 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-010683 · doc4.xml · nonDerivative · entry 2 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 13,277 F3 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Side Fund IV, L.P. ("VSF IV") without consideration to its partners. F4 · ownership.nature: These securities are held of record by VSF IV. VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 20, 2018 Filed Apr 24, 2018 23:42 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 497,053 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-010683 · doc4.xml · nonDerivative · entry 1 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,238,979 F1 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital IV, L.P. ("VVC IV") without consideration to its partners. F2 · ownership.nature: These securities are held of record by VVC IV. Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 22, 2017 Filed Dec 27, 2017 21:14 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 3,059 | $20.29 | $62,070.47 |
DisclosureSEC source: 0000899243-17-029615 · doc4.xml · nonDerivative · entry 1 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,959 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.20 to $20.42, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 27, 2017 Filed Nov 28, 2017 21:11 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 200 | $20.24 | $4,048.00 |
DisclosureSEC source: 0000899243-17-027487 · doc4.xml · nonDerivative · entry 2 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,018 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 24, 2017 Filed Nov 28, 2017 21:11 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,700 | $20.21 | $34,357.85 |
DisclosureSEC source: 0000899243-17-027487 · doc4.xml · nonDerivative · entry 1 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,218 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.20 to $20.25, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 05, 2017 Filed Sep 8, 2017 01:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Stock | 9,918 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-051985 · doc4.xml · nonDerivative · entry 13 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,918 F22 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VV IV, VV V and VV V CAN to their members or partners. Read SEC document |
| September 05, 2017 Filed Sep 8, 2017 01:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Stock | 1,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-051985 · doc4.xml · nonDerivative · entry 12 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 0 F21 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV V CAN without consideration to its partners. F20 · ownership.nature: The shares are held VV V CAN. Read SEC document |
| September 05, 2017 Filed Sep 8, 2017 01:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Stock | 1,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-051985 · doc4.xml · nonDerivative · entry 11 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 1,240 F19 · kind: Represents a change in the form of ownership of VV V CAN by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC CAN. F20 · ownership.nature: The shares are held VV V CAN. Read SEC document |
| September 05, 2017 Filed Sep 8, 2017 01:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Stock | 17,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-051985 · doc4.xml · nonDerivative · entry 10 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 0 F18 · kind: . Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV V without consideration to its members. F17 · ownership.nature: The shares are held VV V. Read SEC document |
| September 05, 2017 Filed Sep 8, 2017 01:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Stock | 17,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-051985 · doc4.xml · nonDerivative · entry 9 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 17,283 F16 · kind: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC V, VAF V and VOA. F17 · ownership.nature: The shares are held VV V. Read SEC document |
| September 05, 2017 Filed Sep 8, 2017 01:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Stock | 292,529 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-051985 · doc4.xml · nonDerivative · entry 8 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 0 F15 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV IV without consideration to its members. F14 · ownership.nature: The shares are held VV IV. Read SEC document |
| September 05, 2017 Filed Sep 8, 2017 01:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Stock | 292,529 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-051985 · doc4.xml · nonDerivative · entry 7 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 292,529 F13 · kind: Represents a change in the form of ownership of VV IV by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC IV and VSF IV. F14 · ownership.nature: The shares are held VV IV. Read SEC document |
| September 05, 2017 Filed Sep 8, 2017 01:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Stock | 26,491 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-051985 · doc4.xml · nonDerivative · entry 6 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 52,987 F11 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA") without consideration to its partners. F12 · ownership.nature: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 05, 2017 Filed Sep 8, 2017 01:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Stock | 61,993 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-051985 · doc4.xml · nonDerivative · entry 5 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 123,994 F9 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital V (Canada) LP ("VVC CAN") without consideration to its partners. F10 · ownership.nature: These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the shares through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 05, 2017 Filed Sep 8, 2017 01:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Stock | 23,899 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-051985 · doc4.xml · nonDerivative · entry 4 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 47,801 F7 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Affiliates Fund V, L.P. ("VAF V") without consideration to its partners. F8 · ownership.nature: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 05, 2017 Filed Sep 8, 2017 01:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Stock | 814,599 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-051985 · doc4.xml · nonDerivative · entry 3 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 1,629,204 F5 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital V, L.P. ("VVC V") without consideration to its partners. F6 · ownership.nature: These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 05, 2017 Filed Sep 8, 2017 01:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Stock | 8,110 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-051985 · doc4.xml · nonDerivative · entry 2 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 16,224 F3 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Side Fund IV, L.P. ("VSF IV") without consideration to its partners. F4 · ownership.nature: These securities are held of record by VSF IV. VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 05, 2017 Filed Sep 8, 2017 01:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Stock | 1,368,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-051985 · doc4.xml · nonDerivative · entry 1 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 2,736,032 F1 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital IV, L.P. ("VVC IV") without consideration to its partners. F2 · ownership.nature: These securities are held of record by VVC IV. Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 19:11 UTC | Adverum Biotechnologies, Inc. ADVM · Entity 71889 | GrantStock Option (Right to Buy) · Derivative | 33,602 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001209191-17-039967 · doc4.xml · derivative · entry 2 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,602 Underlying: Common Stock · 33,602 shares Expires 2027-06-11 Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 19:11 UTC | Adverum Biotechnologies, Inc. ADVM · Entity 71889 | GrantCommon Stock | 22,727 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-039967 · doc4.xml · nonDerivative · entry 1 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,380 F1 · shares: Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock of the Issuer for each one (1) RSU upon the vesting thereof. Such RSUs vest with respect to 100% of the shares subject thereto on June 12, 2018. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 20:30 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $13.62 | $0.00 |
DisclosureSEC source: 0000899243-17-015165 · doc4.xml · derivative · entry 1 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2027-05-31 F2 · shares: One-half of the securities acquired as reported in column 5 were granted to the Reporting Person and one-half were granted to Bradley Bolzon, each grant as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person and one-half of the reported securities are held by Mr. Bolzon. Each of the Reporting Person and Mr. Bolzon are managing members of Versant Venture Management, LLC and pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Bolzon are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC. F3 · shares: (Continued from Footnote 2) The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F1 · derivative.exercise_date: These options were granted on May 31, 2017 with 100% of the shares vesting in 12 equal monthly installments beginning June 30, 2017. F2 · derivative.underlying_shares: One-half of the securities acquired as reported in column 5 were granted to the Reporting Person and one-half were granted to Bradley Bolzon, each grant as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person and one-half of the reported securities are held by Mr. Bolzon. Each of the Reporting Person and Mr. Bolzon are managing members of Versant Venture Management, LLC and pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Bolzon are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC. F3 · derivative.underlying_shares: (Continued from Footnote 2) The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F2 · balance_after: One-half of the securities acquired as reported in column 5 were granted to the Reporting Person and one-half were granted to Bradley Bolzon, each grant as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person and one-half of the reported securities are held by Mr. Bolzon. Each of the Reporting Person and Mr. Bolzon are managing members of Versant Venture Management, LLC and pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Bolzon are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC. F3 · balance_after: (Continued from Footnote 2) The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F2 · ownership.nature: One-half of the securities acquired as reported in column 5 were granted to the Reporting Person and one-half were granted to Bradley Bolzon, each grant as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person and one-half of the reported securities are held by Mr. Bolzon. Each of the Reporting Person and Mr. Bolzon are managing members of Versant Venture Management, LLC and pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Bolzon are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC. F3 · ownership.nature: (Continued from Footnote 2) The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 28, 2017 Filed May 1, 2017 20:20 UTC | Adverum Biotechnologies, Inc. ADVM · Entity 71889 | GrantCommon Stock | 2,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-029044 · doc4.xml · nonDerivative · entry 1 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,653 F1 · shares: The Reporting Person is entitled to receive one (1) share of Common Stock of the Issuer for each one (1) restricted stock unit. Read SEC document |
| March 31, 2017 Filed Apr 3, 2017 17:57 UTC | Adverum Biotechnologies, Inc. ADVM · Entity 71889 | GrantCommon Stock | 3,704 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-024259 · doc4.xml · nonDerivative · entry 1 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,430 F1 · shares: The Reporting Person is entitled to receive one (1) share of Common Stock of the Issuer for each one (1) restricted stock unit. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 16:58 UTC | Adverum Biotechnologies, Inc. ADVM · Entity 71889 | GrantCommon Stock | 3,774 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-016750 · doc4.xml · nonDerivative · entry 1 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,726 F1 · shares: The Reporting Person is entitled to receive one (1) share of Common Stock of the Issuer for each one (1) restricted stock unit. Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 16:41 UTC | Adverum Biotechnologies, Inc. ADVM · Entity 71889 | GrantCommon Stock | 3,449 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-007125 · doc4.xml · nonDerivative · entry 1 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,952 F1 · shares: The Reporting Person is entitled to receive one (1) share of Common Stock of the Issuer for each one (1) restricted stock unit. Read SEC document |
| December 30, 2016 Filed Jan 3, 2017 17:27 UTC | Adverum Biotechnologies, Inc. ADVM · Entity 71889 | GrantCommon Stock | 3,449 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-000376 · doc4.xml · nonDerivative · entry 1 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,503 F1 · shares: The Reporting Person is entitled to receive one (1) share of Common Stock of the Issuer for each one (1) restricted stock unit. Read SEC document |
| November 30, 2016 Filed Dec 1, 2016 18:05 UTC | Adverum Biotechnologies, Inc. ADVM · Entity 71889 | GrantCommon Stock | 3,509 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-152742 · doc4.xml · nonDerivative · entry 1 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,054 F1 · shares: The Reporting Person is entitled to receive one (1) share of Common Stock of the Issuer for each one (1) restricted stock unit. Read SEC document |
| October 31, 2016 Filed Nov 1, 2016 18:48 UTC | Adverum Biotechnologies, Inc. ADVM · Entity 71889 | GrantCommon Stock | 3,390 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-147719 · doc4.xml · nonDerivative · entry 1 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,545 F1 · shares: The Reporting Person is entitled to receive one (1) share of Common Stock of the Issuer for each one (1) restricted stock unit. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries B Preferred Shares · Derivative | 5,774 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · derivative · entry 34 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 5,774 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F8 · ownership.nature: These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries B Preferred Shares · Derivative | 13,180 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · derivative · entry 33 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 13,180 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F7 · ownership.nature: These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the shares through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries B Preferred Shares · Derivative | 5,210 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · derivative · entry 32 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 5,210 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F6 · ownership.nature: These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries B Preferred Shares · Derivative | 173,167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · derivative · entry 31 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 173,167 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F5 · ownership.nature: These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries B Preferred Shares · Derivative | 1,454 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · derivative · entry 30 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,454 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F4 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries B Preferred Shares · Derivative | 231,077 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · derivative · entry 29 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 231,077 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F3 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries A-3 Preferred Shares · Derivative | 73,704 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · derivative · entry 28 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 73,704 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F8 · ownership.nature: These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries A-3 Preferred Shares · Derivative | 168,224 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · derivative · entry 27 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 168,224 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F7 · ownership.nature: These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the shares through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries A-3 Preferred Shares · Derivative | 66,490 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · derivative · entry 26 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 66,490 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F6 · ownership.nature: These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries A-3 Preferred Shares · Derivative | 2,210,417 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · derivative · entry 25 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,210,417 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F5 · ownership.nature: These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries A-2 Preferred Shares · Derivative | 19,524 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · derivative · entry 24 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 19,524 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F4 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries A-2 Preferred Shares · Derivative | 3,100,477 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · derivative · entry 23 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 3,100,477 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F3 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries A-1 Preferred Shares · Derivative | 2,754 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · derivative · entry 22 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,754 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F4 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries A-1 Preferred Shares · Derivative | 437,247 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · derivative · entry 21 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 437,247 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F3 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 5,774 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · nonDerivative · entry 19 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 79,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F8 · ownership.nature: These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 73,704 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · nonDerivative · entry 18 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 73,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F8 · ownership.nature: These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | PurchaseCommon Stock | 4,583 | $14.00 | $64,162.00 |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · nonDerivative · entry 17 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 185,987 F7 · ownership.nature: These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the shares through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 13,180 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · nonDerivative · entry 16 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 181,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F7 · ownership.nature: These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the shares through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 168,224 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · nonDerivative · entry 15 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 168,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F7 · ownership.nature: These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the shares through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Stock | 5,210 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163805 · a4.xml · nonDerivative · entry 14 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 71,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F6 · ownership.nature: These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.